TAO patients with or without DON were recruited from Zhongshan Ophthalmic Center from April 1, 2018 to July 1, 2018. Age- and sex-matched healthy subjects were enrolled simultaneously. Written informed consent was obtained prior to any examination. This study was conducted adhering to the tenets of the Declaration of Helsinki.
The diagnosis of TAO and severity classification were made using the European Group on Graves' Orbitopathy criteria.
21 The TAO patients meeting the following criteria were included in the study: (1) age of
>18 years, (2) spherical equivalent of <3.00 diopters (D), (3) clear refractive media allowing sufficient image quality, and (4) no treatment with systemic glucocorticoids for at least 3 months prior to the study. The common exclusion criteria for all subjects were as follows: (1) any systemic diseases rather than thyroid disorders, (2) any history of ocular surgery or ocular trauma, and (3) any ophthalmopathies (e.g., glaucoma, diabetic retinopathy, and uveitis). DON was diagnosed based on clinical findings
6,22,23: decreased visual acuity (the best-corrected visual acuity [BCVA] in logMAR visual chart, >0.2), apparent visual field (VF) defect (mean deviation [MD] in Humphrey perimetry, <−10 dB), relative afferent pupillary defect when unilaterally affected, abnormal pattern visual evoked potentials test (latency delay and amplitude reduction), and evident apical crowding in orbital computed tomography or and/or magnetic resonance imaging. As image quality was associated with the vessel density measures,
24 OCT-A scans with inadequate quality were excluded: (1) signal strength index of <45, (2) motion artifacts visible on the en face angiogram, (3) local weak signal, and (4) images off-center on fovea or disc.